ARTV Artiva Biotherapeutics, Inc.
Healthcare$7.67-2.54%ClosedMarket Cap: $189.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.21
P/S
0.00
EV/EBITDA
-2.06
DCF Value
$0.64
FCF Yield
-41.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.2%
ROA
-82.2%
ROIC
-93.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-24.4M | $-23.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-21.9M | $-20.8M | $— | — |
| FY null | $0.00 | -Infinity% | $-90.6M | $-83.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-22.9M | $-21.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-22.8M | $-21.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-22.2M | $-20.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-18.3M | $-9.2M | $— | — |
| FY null | $251.0K | 100.0% | $-67.3M | $-58.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-18.3M | $-17.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-16.2M | $-17.8M | $— | — |
| Q1 null | $251.0K | 100.0% | $-14.5M | $-14.0M | $— | — |
| Q4 2023 | $2.4M | 100.0% | $-12.0M | $-12.0M | $-0.54 | — |